Statistics

	Views
The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control	66

Select a period of time:

	Views
The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control	13

RUNA digital repository